CRNX
Price
$26.85
Change
-$1.03 (-3.69%)
Updated
Aug 8 closing price
Capitalization
2.52B
88 days until earnings call
IONS
Price
$41.64
Change
+$0.59 (+1.44%)
Updated
Aug 8 closing price
Capitalization
6.64B
81 days until earnings call
Interact to see
Advertisement

CRNX vs IONS

Header iconCRNX vs IONS Comparison
Open Charts CRNX vs IONSBanner chart's image
Crinetics Pharmaceuticals
Price$26.85
Change-$1.03 (-3.69%)
Volume$2M
Capitalization2.52B
Ionis Pharmaceuticals
Price$41.64
Change+$0.59 (+1.44%)
Volume$1.74M
Capitalization6.64B
CRNX vs IONS Comparison Chart in %
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. IONS commentary
Aug 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a StrongBuy and IONS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 10, 2025
Stock price -- (CRNX: $26.85 vs. IONS: $41.64)
Brand notoriety: CRNX and IONS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 271% vs. IONS: 89%
Market capitalization -- CRNX: $2.52B vs. IONS: $6.64B
CRNX [@Biotechnology] is valued at $2.52B. IONS’s [@Biotechnology] market capitalization is $6.64B. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • IONS’s FA Score: 0 green, 5 red.
According to our system of comparison, IONS is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 4 TA indicator(s) are bullish while IONS’s TA Score has 4 bullish TA indicator(s).

  • CRNX’s TA Score: 4 bullish, 6 bearish.
  • IONS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, IONS is a better buy in the short-term than CRNX.

Price Growth

CRNX (@Biotechnology) experienced а -3.56% price change this week, while IONS (@Biotechnology) price change was -3.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.25%. For the same industry, the average monthly price growth was +6.85%, and the average quarterly price growth was +13.24%.

Reported Earning Dates

CRNX is expected to report earnings on Nov 06, 2025.

IONS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+0.25% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IONS($6.64B) has a higher market cap than CRNX($2.52B). IONS YTD gains are higher at: 19.108 vs. CRNX (-47.487). IONS has higher annual earnings (EBITDA): -170.69M vs. CRNX (-373.49M). IONS has more cash in the bank: 2.29B vs. CRNX (1.27B). CRNX has less debt than IONS: CRNX (50.8M) vs IONS (1.42B). IONS has higher revenues than CRNX: IONS (944M) vs CRNX (760K).
CRNXIONSCRNX / IONS
Capitalization2.52B6.64B38%
EBITDA-373.49M-170.69M219%
Gain YTD-47.48719.108-249%
P/E RatioN/AN/A-
Revenue760K944M0%
Total Cash1.27B2.29B56%
Total Debt50.8M1.42B4%
FUNDAMENTALS RATINGS
CRNX vs IONS: Fundamental Ratings
CRNX
IONS
OUTLOOK RATING
1..100
5373
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
73100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
8746
P/E GROWTH RATING
1..100
10067
SEASONALITY SCORE
1..100
3650

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRNX's Valuation (86) in the Pharmaceuticals Major industry is in the same range as IONS (96) in the Biotechnology industry. This means that CRNX’s stock grew similarly to IONS’s over the last 12 months.

CRNX's Profit vs Risk Rating (73) in the Pharmaceuticals Major industry is in the same range as IONS (100) in the Biotechnology industry. This means that CRNX’s stock grew similarly to IONS’s over the last 12 months.

CRNX's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as IONS (98) in the Biotechnology industry. This means that CRNX’s stock grew similarly to IONS’s over the last 12 months.

IONS's Price Growth Rating (46) in the Biotechnology industry is somewhat better than the same rating for CRNX (87) in the Pharmaceuticals Major industry. This means that IONS’s stock grew somewhat faster than CRNX’s over the last 12 months.

IONS's P/E Growth Rating (67) in the Biotechnology industry is somewhat better than the same rating for CRNX (100) in the Pharmaceuticals Major industry. This means that IONS’s stock grew somewhat faster than CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXIONS
RSI
ODDS (%)
Bullish Trend 6 days ago
77%
Bearish Trend 2 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
68%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
68%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 2 days ago
64%
Declines
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 4 days ago
68%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
73%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FDTIX40.910.31
+0.76%
Fidelity Advisor Diversified Stock I
LMCTX32.270.16
+0.50%
Lord Abbett Mid Cap Stock R5
FFMMX60.290.28
+0.47%
American Funds American Mutual 529-F-2
ACBYX15.220.05
+0.33%
American Beacon Balanced Y
INDSX17.71-0.13
-0.73%
ALPS/Kotak India ESG II

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
-3.69%
XNCR - CRNX
62%
Loosely correlated
-1.23%
IDYA - CRNX
57%
Loosely correlated
+3.08%
RVMD - CRNX
56%
Loosely correlated
+0.17%
TRDA - CRNX
55%
Loosely correlated
-2.08%
SYRE - CRNX
55%
Loosely correlated
N/A
More